Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 26, 2012, Pages 10534-10539

  Vicente Dueñas, Carolina ^a   Fontán, Lorena ^b   Gonzalez Herrero, Ines ^a   Romero Camarero, Isabel ^a   Segura, Victor ^b   Aznar, M Angela ^b   Alonso Escudero, Esther ^a   Campos Sanchez, Elena ^c   Ruiz Roca, Lucía ^a   Barajas Diego, Marcos ^a   Sagardoy, Ainara ^b   Martinez Ferrandis, Jose I ^b   Abollo Jimenez, Fernando ^c   Bertolo, Cristina ^b   Peñuelas, Ivan ^d   Garcia Criado, Francisco J ^a   García Cenador, María B ^a   Tousseyn, Thomas ^e   Agirre, Xabier ^b,d   Prosper, Felipe ^b,d   Garcia Bragado, Federico ^f   McPhail, Ellen D ^g   Lossos, Izidore S ^h   Du, Ming Qing ⁱ   Flores, Teresa ^a   Hernandez Rivas, Jesus M ^a   Gonzalez, Marcos ^a   Salar, Antonio ^j   Bellosillo, Beatriz ^j   Conde, Eulogio ^k   Siebert, Reiner ^l   Sagaert, Xavier ^e   Cobaleda, Cesar ^c   Sanchez Garcia, Isidro ^a   Martinez Climent, Jose A ^b   more..

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Universidad Pública de Navarra   (Spain)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

Cancer stem cells; Molecular directed therapy; Transgenic mice; Tumor reprogramming

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE DELETION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; CASPASES; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NF-KAPPA B; ONCOGENES; TRANSCRIPTION, GENETIC;

MUS; MUS MUSCULUS;

EID: 84862990370     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204127109     Document Type: Article

References (26)

1. Farinha P, Gascoyne RD (2005) Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23:6370-6378. (Pubitemid 46218849)
2. Isaacson PG, Du MQ (2004) MALT lymphoma: From morphology to molecules. Nat Rev Cancer 4:644-653. (Pubitemid 39025059)
3. Sagaert X, De Wolf-Peeters C, Noels H, Baens M (2007) The pathogenesis of MALT lymphomas: Where do we stand? Leukemia 21:389-396.
4. Dierlamm J, et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601-3609. (Pubitemid 29249804)
5. Sanchez-Izquierdo D, et al. (2003) MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101:4539-4546. (Pubitemid 36857825)
6. Streubel B, et al. (2003) T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101:2335-2339. (Pubitemid 36302078)
7. Thome M, Charton JE, Pelzer C, Hailfinger S (2010) Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2:a003004.
8. Coornaert B, et al. (2008) T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9:263-271. (Pubitemid 351267323)
9. Rebeaud F, et al. (2008) The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 9:272-281. (Pubitemid 351267324)
10. Wright G, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:9991-9996. (Pubitemid 37087056)
11. Staudt LM (2010) Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2:a000109.
12. Baens M, et al. (2006) Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 66:5270-5277. (Pubitemid 43844951)
13. Li Z, et al. (2009) Emu-BCL10 mice exhibit constitutive activation of both canonical and non-canonical NF-kappaB pathways generating marginal zone (MZ) B cell expansion as a precursor to splenic MZ lymphoma. Blood 114:4158-4168.
14. Ferch U, et al. (2009) Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 206:2313-2320.
15. Hailfinger S, et al. (2009) Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 106:19946-19951.
16. Pérez-Caro M, et al. (2009) Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 28:8-20.
17. Choi WW, et al. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502.
18. Visco C, et al. (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 10.1038/leu.2012.83.
19. Shaffer AL, et al. (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21:81-93. (Pubitemid 38925269)
20. Du M, Peng H, Singh N, Isaacson PG, Pan L (1995) The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587-4593.
21. Jacks T, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7.
22. Sagaert X, et al. (2006) Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24:2490-2497. (Pubitemid 46630625)
23. Lenz G, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105:13520-13525.
24. Dunleavy K, et al. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076.
25. Quivoron C, et al. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20:25-38.
26. Kikushige Y, et al. (2011) Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-259.